Previous close | 15.48 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 718 |
Market cap | N/A |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | 0.17 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SLR Investment Corp. (the “Company”) (NASDAQ: SLRC) today announced that it will release its financial results for the quarter ended March 31, 2024 on Wednesday, May 8, 2024 after the close of the financial markets. The Company will host an earnings conference call and audio webcast at 10:00 a.m. (Eastern Time) on Thursday, May 9, 2024. All interested parties may participate in the conference call by dialing (800) 445-7795 approximately 5-10 minutes p
Net Investment Income of $0.44 Per Share for Q4 2023; Declared Quarterly Distribution of $0.41 Per Share; Stable NAV and Strong Portfolio Credit Quality NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company”, “SLRC”, “we”, or “our”) today reported net investment income of $23.9 million, or $0.44 per share, for the fourth quarter of 2023. As of December 31, 2023, net asset value (NAV) was $18.09 per share, compared to $18.06 as of September 30, 2023. In the
CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, today announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility. The equity financing was led by Revelation Partners, SPR’s lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual C